Erythema Market

Market Overview:

The 7 major erythema markets are expected to exhibit a CAGR of 4.38% during 2024-2034.

The erythema market has been comprehensively analyzed in IMARC's new report titled "Erythema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Erythema is a medical term that refers to redness of the skin, typically caused by increased blood flow or inflammation. The primary symptom of erythema is visible redness, which may appear as a localized area or affect a larger region of the body. Depending on the underlying cause and associated inflammatory processes, erythema may be accompanied by various additional indications, such as warmth, itching, pain, swelling, burning sensation, etc. These symptoms can vary in severity and may be present for a short duration or persist over a longer period. The diagnosis of erythema involves a comprehensive evaluation by a healthcare professional, typically a dermatologist or primary care physician. The healthcare provider will assess the appearance of the redness, its distribution, any associated symptoms, and factors that may have triggered or exacerbated the disease conditions. In some cases, additional diagnostic procedures may be necessary, such as skin biopsies, blood tests, allergy testing, etc., to determine the underlying cause of erythema. These techniques can help to identify specific skin conditions, allergic reactions, infections, or systemic diseases contributing to the redness.

The escalating cases of chronic inflammatory skin disorders, such as eczema, psoriasis, rosacea, seborrheic dermatitis, etc., which cause blood vessels to dilate, thereby resulting in redness and inflammation, are primarily driving the erythema market. In addition to this, the rising prevalence of several associated risk factors, including allergic reactions, bacterial infections, exposure to certain chemicals, sunburn, inherited conditions like hereditary angioedema and familial Mediterranean fever, etc., is also bolstering the market growth. Furthermore, the inflating adoption of topical calcineurin inhibitors, such as tacrolimus and pimecrolimus, to modulate the immune response in the skin and alleviate inflammation is acting as another significant growth-inducing factor. Additionally, the emerging popularity of vascular laser therapy, which targets blood vessels causing erythema and selectively destroys them, thereby reducing redness, is also creating a positive outlook for the market. Apart from this, the escalating utilization of neurokinin receptor antagonists for inhibiting the release of pro-inflammatory neuropeptides and attenuating the neurogenic component associated with the ailment is expected to drive the erythema market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the erythema market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for erythema and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the erythema market in any manner.

Key Highlights:

• Erythema is more prevalent in children (e.g., erythema infectiosum) and adolescents.
• Erythema nodosum is more common in women, particularly between the ages of 20 and 40.
• Erythema caused by infectious diseases (such as erythema infectiosum) typically has seasonal outbreaks, notably in warmer regions throughout the spring and winter months.
• About 90% of cases of erythema multiforme are caused by infections, particularly herpes simplex virus.

Drugs:

Rhofade (Oxymetazoline) is indicated for the topical treatment of chronic facial erythema related to rosacea in adults. Rhofade is an alpha1A adrenoceptor agonist. It acts by constricting blood vessels in the skin.

Mirvaso (Brimonidine topical gel) (0.33%) is an alpha-adrenergic agonist used to treat persistent rosacea erythema in persons aged 18 and above. MIRVASO topical gel may minimize erythema by causing vasoconstriction.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the erythema market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the erythema market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current erythema marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the erythema market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the erythema market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the erythema market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of erythema across the seven major markets?
• What is the number of prevalent cases (2018-2034) of erythema by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of erythema by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with erythema across the seven major markets?
• What is the size of the erythema patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of erythema?
• What will be the growth rate of patients across the seven major markets?
   

Erythema: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for erythema drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the erythema market?
• What are the key regulatory events related to the erythema market?
• What is the structure of clinical trial landscape by status related to the erythema market?
• What is the structure of clinical trial landscape by phase related to the erythema market?
• What is the structure of clinical trial landscape by route of administration related to the erythema market?